Diligence memo · auto-generated · as of July 2, 2026

Aquarius Biotechnologies, Inc.

Aquarius Biotechnologies, Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Aquarius Biotechnologies, Inc. operates in Biotechnology, based in CHICAGO.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Aquarius Biotechnologies, Inc. has raised $327K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $327K on 2013-09-25.

Most recent recorded round closed around 2013-09-25.

Valuation (modeled)modeled

Provath models Aquarius Biotechnologies, Inc. at approximately $18M (range $175K–$205M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.14× the median modeled value of Pre-Seed Biotechnology companies in 2013–2015 (131 peers) — value vs value, same stage and era. Within the normal band (114% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 12.8 yr ago; this sector typically re-raises about every 14 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 8% of Biotechnology peers (4293 compared).

Modeled value ranks above 27% of those peers.

Closest niche peers: Imanis Life Sciences, LLC, Truminim, LLC, Direct Spinal Therapeutics, Inc., Universal Biosensors Inc, One World Lab, Inc..

Peoplefiled

5 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.